SCHEMBL145671

SCHEMBL145671

CCOC(=O)c1ccc2nc(Br)sc2c1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 10/20 0.67
RAB9A P51151 8/20 0.67
SMN1; SMN2 Q16637 8/20 0.67
STAT1 P42224 1/20 0.67
ALDH1A1 P00352 5/20 0.62
KDM4E B2RXH2 4/20 0.62
MAPT P10636 3/20 0.62
HPGD P15428 2/20 0.62
ALPL P05186 1/20 0.62
GAA P10253 1/20 0.62
HSD17B10 Q99714 3/20 0.57
TP53 P04637 2/20 0.57
NFKB1 P19838 1/20 0.57
NFKB2 Q00653 1/20 0.57
RELA Q04206 1/20 0.57
USP2 O75604 1/20 0.56
ACP1 P24666 1/20 0.54
HTT P42858 1/20 0.52
SIRT2 Q8IXJ6 1/20 0.51
MEN1 O00255 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30189826 1.00 NPC1 (0.67) NPC1RAB9ASMN1; SMN2STAT1ALDH1A1
SCHEMBL9304903 0.89 NPC1 (0.53) NPC1RAB9ASMN1; SMN2STAT1ALDH1A1
SCHEMBL4667327 0.87 NPC1 (0.68) NPC1RAB9ASMN1; SMN2STAT1ALDH1A1
SCHEMBL73574 0.84 RAB9A (0.65) NPC1RAB9ASMN1; SMN2STAT1ALDH1A1
SCHEMBL6844717 0.84 NPC1 (0.65) NPC1RAB9ASMN1; SMN2STAT1ALDH1A1
SCHEMBL19029298 0.84 NPC1 (0.65) NPC1RAB9ASMN1; SMN2STAT1ALDH1A1
SCHEMBL1094691 0.84 NPC1 (0.65) NPC1RAB9ASMN1; SMN2STAT1ALDH1A1
SCHEMBL8975774 0.84 NPC1 (0.65) NPC1RAB9ASMN1; SMN2STAT1ALDH1A1
SCHEMBL1980717 0.84 PIK3CA (0.66) NPC1RAB9ASMN1; SMN2STAT1ALDH1A1
SCHEMBL18585932 0.82 NPC1 (0.77) NPC1RAB9ASMN1; SMN2STAT1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 250 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12636385-B2 Selective ligands for tau aggregates SENTONIX, INC. (US) 2026-05-26 US disclosed
US-20250282742-A1 BENZOFURAN DERIVATIVES FOR TARGETING AUTOPHAGY Automera PTE. LTD (SG) 2025-09-11 US disclosed
US-12258342-B2 Class of DNA gyrase and/or topoisomerase IV inhibitors with activity against gram-positive and gram-negative bacteria UNIVERZA V LJUBLJANI (SI) 2025-03-25 US disclosed
US-12060347-B2 Bicyclic heteroaryl substituted compounds BRISTOL-MYERS SQUIBB COMPANY (US) 2024-08-13 US disclosed
US-20240150339-A1 Compounds and Their Use as PDE4 Activators MIRONID LIMITED (GB) 2024-05-09 US disclosed
EP-4291557-A1 COMPOUNDS AND THEIR USE AS PDE4 ACTIVATORS Mironid Limited (GB) 2023-12-20 EP disclosed
WO-2023218023-A1 THIAZOLOARYL-METHYL SUBSTITUTED CYCLIC HYDRAZINE-N-CARBOXAMIDE DERIVATIVES IDORSIA PHARMACEUTICALS LTD (CH) 2023-11-16 WO disclosed
CN-111278821-B Spiro compounds as farnesol X receptor modulators 百时美施贵宝公司 2023-10-03 CN disclosed
CN-116848107-A Compounds and their use as PDE4 activators 米罗尼德有限公司 2023-10-03 CN disclosed
CN-109689647-B Bicyclic heteroaryl substituted compounds 百时美施贵宝公司 2023-01-20 CN disclosed
WO-1998043975-A1 PYROLOPYRROLONE DERIVATIVES GLAXO GROUP LIMITED (GB) 1998-10-08 WO disclosed
EP-0750620-A4 CARBAPENEM COMPOUNDS, COMPOSITIONS AND METHODS OF TREATMENT MERCK & CO INC (US) 1997-07-16 EP disclosed
EP-0750620-A1 CARBAPENEM COMPOUNDS, COMPOSITIONS AND METHODS OF TREATMENT MERCK & CO. INC. (US) 1997-01-02 EP disclosed
US-5565445-A ANTIBIOTICS, USEFUL AGAINST METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS OR STAPHYLOCOCCUS EPIDERMIDIS AND METHICILLIN RESITANT COAGULASE NEGATIVE STAPHYLOCOCCI MERCK & CO., INC. (US) 1996-10-15 US disclosed
US-5541176-A ANTIBIOTICS, USEFUL AGAINST METHICILLIN RESISTANT STAPHYLOCOCCUS MERCK & CO., INC. (US) 1996-07-30 US disclosed
US-5538964-A ANTIBIOTICS FOR BACTERICIDES MERCK & CO., INC. (US) 1996-07-23 US disclosed
US-5498777-A 3-thioheteroaryl cephalosporin compounds, compositions and methods of use MERCK & CO., INC. (US) 1996-03-12 US disclosed
US-5496816-A Carbapenem antibacterial compounds, compositions containing such compounds and methods of treatment MERCK & CO., INC. (US) 1996-03-05 US disclosed
WO-1996002548-A1 3-THIOHETEROARYL CEPHALOSPORIN COMPOUNDS, COMPOSITIONS AND METHODS OF USE MERCK & CO., INC. (US) 1996-02-01 WO disclosed
WO-1995025108-A1 CARBAPENEM COMPOUNDS, COMPOSITIONS AND METHODS OF TREATMENT MERCK & CO., INC. (US) 1995-09-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12060347-B2 Bicyclic heteroaryl substituted compounds F2, F2RL3, F12 NPC1 2194/4885RAB9A 748/4885SMN1; SMN2 3957/4885
US-12636385-B2 Selective ligands for tau aggregates MAPT, PSEN2, PSEN1 NPC1 242/4885RAB9A 1472/4885SMN1; SMN2 45/4885
US-20250282742-A1 BENZOFURAN DERIVATIVES FOR TARGETING AUTOPHAGY SQSTM1, BECN1, TFEB NPC1 293/4885RAB9A 238/4885SMN1; SMN2 477/4885
US-20240150339-A1 Compounds and Their Use as PDE4 Activators PDE4A, PDE4B, PDE4C NPC1 3795/4885RAB9A 1715/4885SMN1; SMN2 1885/4885
US-12258342-B2 Class of DNA gyrase and/or topoisomerase IV inhibitors with activity against gram-positive and gram-negative bacteria TOP1, TOP2A, TOP2B NPC1 4546/4885RAB9A 3924/4885SMN1; SMN2 4529/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.